Author: Karl Schmieder

The genetic modification of biological systems already comprises some $350 billion or nearly three percent of the U.S. Gross Domestic product. Rob Carlson, managing director Bioeconomy Capital and author of Biology is Technology terms this the “Genetically Modified Domestic Product.”   This bioeconomy includes crops, drugs, fuels, industrial enzymes and materials. When he published Biology is Technology, Carlson pointed out: Current biotechnology demonstrates impressive and disproportionate economic performance despite the fact that the underlying technology is presently immature compared with other sectors of the economy. “Impressive and disproportionate economic performance” means that using biotechnology enables fewer people to create...